Pharmacogenetics of breast cancer: towards the individualization of therapy

Pharmacogenetics, generally referred to as the study of genetic variation that gives rise to differing response to drugs, is becoming more relevant in the diagnosis, treatment, and recovery of cancer patients. The problem faced when treating cancer is the outstanding varied efficacy between success and failure. Unpredictability between a population of patients who are affected with the same occurring malignancy can show varying associated toxicities in drug treatment ranging from zero effect through lethal doses. Since the chemotherapeuticagent is often developed to fit the average patient the unfortunate result isthat approximately 40% of patients may be receiving the wrong drug. However, using pharmacogenetics there are promising advancements in the development of effective agents which will enable ‘personalized cancer chemotherapy’ to become routine for the clinical practice. This individualization is most advanced in the field of breast cancer; while many breast oncologists are individualizing techniques based on specific profiles, within 10 years it is likely all breast oncologists will be using RT-PCR, FISH-based multiplexed arrays, or a similar testing regime for patient individualization therapy. INDICE: Pharmacogenomic approaches. Individualized kinetics and dosing. Clasical IHC and FISH state of the art. Affy-based chemo and dosing. Panoply of genomic approaches. Epigenetics. Illumina-based platforms. Proteomics. Measurement of Pharmacodynamic endpoints. What tissues are needed + specimen collection

• ISBN: 978-1-4200-5293-0
• Editorial: INFORMA HEALTHCARE BOOKS
• Encuadernacion: Cartoné
• Páginas: 334
• Fecha Publicación: 01/05/2008
• Nº Volúmenes: 1
• Idioma: Inglés